Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma

Dermatologic Surgery

Volumn 39, Issue 7, 2013, Pages 981-987

  Breaker, Kathryn ^a   Naam, Mary ^a   La Rosa, Francisco G ^a   Flaig, Insley P ^a   Flaig, Thomas W ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; SUNITINIB;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CARCINOMA, RENAL CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRROLES; SKIN NEOPLASMS;

EID: 84879880232     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/dsu.12184     Document Type: Article

References (20)

1. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-605.
2. Mendel DB, Laird AD, Xin X, Louie SG, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-37.
3. Wilhelm SM, Carter C, Tang L, Wilkie D, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
4. Wilhelm SM, Adnane L, Newell P, Villanueva A, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-40.
5. Carlomagno F, Anaganti S, Guida T, Salvatore G, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006; 98: 326-34.
6. Wan PT, Garnett MJ, Roe SM, Lee S, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-67.
7. Escudier B, Eisen T, Stadler WM, Szczylik C, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34.
8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
9. Lacouture ME, Desai A, Soltani K, Petronic-Rosic V, et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol 2006; 31: 783-5.
10. Kong HH, Cowen EW, Azad NS, Dahut W, et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007; 56: 171-2.
11. Degen A, Satzger I, Voelker B, Kapp A, et al. Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? Dermatology 2010; 221: 193-6.
12. Smith KJ, Haley H, Hamza S, Skelton HG,. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg 2009; 35: 1766-70.
13. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009; 7: 20-3.
14. Arnault JP, Wechsler J, Escudier B, Spatz A, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009; 27: e59-61.
15. Eisen T, Ahmad T, Flaherty KT, Gore M, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006; 95: 581-6.
16. Zaravinos A, Kanellou P, Baritaki S, Bonavida B, et al. BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma. Cell Cycle 2009; 8: 1402-8.
17. Oberholzer PA, Kee D, Dziunycz P, Sucker A, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30: 316-21.
18. Ji Z, Flaherty KT, Tsao H,. Targeting the RAS pathway in melanoma. Trends Mol Med 2012; 18: 27-35.
19. Chapman PB, Hauschild A, Robert C, Haanen JB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
20. Flaherty KT, Puzanov I, Kim KB, Ribas A, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.